Advancements in chemotherapy and immunotherapy have improved multiple myeloma survival rates, with 5-year relative survival increasing from 37.7% to 60.3% between 2000-2004 and 2015-2019. Treatment ...

Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Strong positive results of a novel combination of two immunotherapy drugs as a treatment for multiple myeloma after other treatments have failed suggest the combination could be a “functional cure,” ...

Arcellx, Inc. (NASDAQ:ACLX) is a clinical-stage biotech company developing innovative cell therapies for cancer and ...

Multiple myeloma is the second most common blood cancer in the United States. Thirty to 50 percent of multiple myeloma patients have extra copies of the gene that encodes the enzyme ADAR1. Using a ...

You have multiple myeloma.” This aggressive and often elusive blood cancer hides behind vague symptoms, leading many down a ...

At the 2025 ASH Annual Meeting and Exposition, researchers presented new findings that may meaningfully affect how patients ...

Every year, an estimated 932 Filipinos are diagnosed with multiple myeloma, a cancer of the blood that develops in plasma cells found in the bone marrow. Plasma cells are a type of white blood cell ...

The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...